ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Shares Up 2.6% – Still a Buy?

Shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) traded up 2.6% during trading on Wednesday. The company traded as high as $55.93 and last traded at $55.81. Approximately 20,231 shares traded hands during trading, a decline of 46% from the average daily volume of 37,778 shares. The stock had previously closed at $54.37.

ALPS Medical Breakthroughs ETF Price Performance

The firm has a 50-day moving average price of $58.94 and a two-hundred day moving average price of $57.07.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SBIO. Harbor Investment Advisory LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the second quarter valued at $29,000. Fulcrum Equity Management bought a new stake in ALPS Medical Breakthroughs ETF in the 2nd quarter valued at $263,000. Rhodes Investment Advisors Inc. ADV bought a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at $266,000. Independent Financial Group LLC bought a new stake in ALPS Medical Breakthroughs ETF in the 1st quarter valued at $283,000. Finally, Kestra Advisory Services LLC raised its stake in shares of ALPS Medical Breakthroughs ETF by 27.6% in the 1st quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock valued at $428,000 after buying an additional 1,772 shares in the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.